Cytonet GmbH & Co. KG Report issue

For profit Phase 2
Founded: Weinheim Germany (2000)
Status: Acquired by Promethera Biosciences (2016)

Organization Overview

First Clinical Trial
2008
NCT00718627
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (1)

human heterologous liver cells (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carbamoyl-Phosphate Synthase I Deficiency Disease (Phase 2)

Citrullinemia (Phase 2)

Disease (Phase 2)

Ornithine Carbamoyltransferase Deficiency Disease (Phase 2)

Urea Cycle Disorders, Inborn (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1